Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: A prospective randomised open-label study

International Journal of Clinical Practice

Volumn 65, Issue 6, 2011, Pages 679-683

  Anagnostis, P ^a   Selalmatzidou, D ^a   Polyzos, S A ^a   Panagiotou, A ^a   Slavakis, A ^a   Panagiotidou, A ^a   Athyros, V G ^b   Karagiannis, A ^b   Mikhailidis, D P ^c   Kita, M ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPOKINES; AGED; BLOOD GLUCOSE; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; SULFONAMIDES; TRIGLYCERIDES;

EID: 79956155395     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02655.x     Document Type: Article

References (28)

1. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP,. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
2. Polyzos SA, Kountouras J, Zavos C,. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9: 299-314.
3. Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
4. Sattar N, Preiss D, Murray HM, et al., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
5. Her AY, Kim JY, Kang SM, et al., Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 2010; 15: 167-74.
6. Park JS, Kim YJ, Choi JY, et al., Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010; 25: 27-35.
7. Ando H, Sugimoto K, Yanagihara H, et al., Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008; 35: 1012-7.
8. Kaya C, Pabuccu R, Cengiz SD, Dünder I,. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 2010; 118: 161-6.
9. Koh KK, Quon MJ, Han SH, et al., Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483-90.
10. Grundy SM, Cleeman JI, Merz CN, et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39. (Pubitemid 38924592)
11. Mojiminiyi OA, Abdella NA,. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med 2010; 48: 1629-34.
12. Katz A, Nambi SS, Mather K, et al., Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10. (Pubitemid 32269192)
13. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP,. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11: 1965-70.
14. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP,. Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes? Curr Pharm Des 2010; 16: 3939-47.
15. ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF,. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005; 35: 558-64. (Pubitemid 41243299)
16. Milionis HJ, Gazi IF, Filippatos TD, et al., Starting with rosuvastatin in primary hyperlipidemia-is there more than lipid lowering? Angiology 2005; 56: 585-92. (Pubitemid 41383312)
17. Bellia A, Rizza S, Galli A, et al., Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010; 210: 199-201.
18. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS,. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009; 63: 1308-13.
19. Chu CH, Lee JK, Lam HC, et al., Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008; 31: 42-7.
20. Huptas S, Geiss HC, Otto C, Parhofer KG,. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 66-9. (Pubitemid 43902683)
21. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK,. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55: 1209-16.
22. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M,. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958-64.
23. Arca M, Cambuli VM, Montali A, et al., Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. Nutr Metab Cardiovasc Dis 2009; 19: 660-6.
24. Hyogo H, Tazuma S, Arihiro K, et al., Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
25. von Eynatten M, Schneider JG, Hadziselimovic S, et al., Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 2005; 28: 754-5. (Pubitemid 40315347)
26. Wallace TM, Levy JC, Matthews DR,. Use and abuse of HOMA modeling. Diabetes Care 2005; 27: 1487-95. (Pubitemid 38680001)
27. Sarafidis PA, Lasaridis AN, Nilsson PM, et al., Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens 2007; 21: 709-16. (Pubitemid 47335301)
28. Antuna-Puente B, Faraj M, Karelis AD, et al., HOMA or QUICKI: is it useful to test the reproducibility of formulas? Diabetes Metab 2008; 34: 294-6.